Market Research Logo

Global Retinoblastoma Treatment Market 2015-2019

Global Retinoblastoma Treatment Market 2015-2019

About retinoblastoma

Cancer occurs when normal cells transform to evade the regular cell cycle process. Retinoblastoma is a rare eye cancer. It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years. The disease affects the retina and is caused by a mutation in the gene RB1. It usually appears in one eye and gradually spreads to the other. Clinically, retinoblastoma is classified into two: unilateral retinoblastoma, tumor in one eye, and bilateral retinoblastoma, tumor in both the eyes.

Technavio's analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.

Technavio's report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the market segmentation. The report includes a discussion of the key vendors operating in this market.Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Baxter
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Spectrum Pharmaceuticals
Other prominent vendors
  • BioLineRx
  • Cellceutix
  • Icon Bioscience
  • Neotropix
  • RXi Pharmaceuticals
  • Recombio
Key market driver
  • Increasing public awareness
  • For a full, detailed list, view our report
Key market challenge
  • Treatment abandonment
  • For a full, detailed list, view our report
Key market trend
  • Localized treatment approach
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Retinoblastoma Treatment Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Retinoblastoma Treatment Market: Baxter, Bristol-Myers Squibb, GlaxoSmithKline, and Spectrum Pharmaceuticals

Other Prominent Vendors in the market are: BioLineRx, Cellceutix, Icon Bioscience, Neotropix, RXi Pharmaceuticals, and Recombio

Commenting on the report, an analyst from Technavio’s team said: “The primary aim of twinning programs was to develop retinoblastoma treatment units. It involved collaboration among governments, private sector institutions, and nongovernmental organizations. These initiatives provide better healthcare facilities in terms of primary care, knowledge of diseases, and more effective decision-making for disease treatment.”

According to the report, awareness campaigns aimed at parents and healthcare professionals lead to early disease diagnosis and improved survival rates. In Honduras, an awareness campaign for the timely recognition of retinoblastoma yielded positive results in terms of disease diagnosis and treatment.

Further, the report states that the social stigma associated with cancer, fear of removal of the eye, and financial burden are the primary reasons for treatment refusal. Tumor progression to other parts of the body and low survival rate further complicates the situation.



Companies Mentioned

Baxter, Bristol-Myers Squibb, GlaxoSmithKline, Spectrum Pharmaceuticals, BioLineRx, Cellceutix, Icon Bioscience, Neotropix, RXi Pharmaceuticals, Recombio

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Retinoblastoma overview
    • Understanding retinoblastoma
    • Etiology
    • Classification
      • Table Classification of retinoblastoma
    • Symptoms
      • Table Symptoms: Percentage occurrence in patients
    • Diagnosis
      • Table Techniques used for diagnosing retinoblastoma
    • Patient examination
    • Imaging tests
    • Biopsy tests
    • Clinical tests
    • Epidemiology
    • Staging
      • Table Intraocular staging
      • Table Extraocular staging
    • Management
      • Table Retinoblastoma: Treatment options
    • Cryotherapy
    • Chemotherapy
    • Photocoagulation
    • Radiation therapy
    • Surgery
    • Thermotherapy
  • Market landscape
    • Market overview
      • Table Global retinoblastoma treatment market 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline Analysis
    • Table Pipeline portfolio
    • Key information of pipeline candidates
  • Market segmentation by therapeutic class of drugs
    • Table Global retinoblastoma treatment market by therapeutic class of drugs
    • Alkylating agents
    • Antimetabolites
    • Microtubule inhibitors
    • Cytotoxic antibiotics
    • Topoisomerase inhibitors
    • Others
  • Market segmentation by disease status
    • Table Global retinoblastoma treatment market by disease type
    • Unilateral retinoblastoma
      • Table Global retinoblastoma treatment market by disease type 2014
    • Bilateral retinoblastoma
  • Geographical segmentation
    • Table Global retinoblastoma treatment market by geography 2014
  • Market growth drivers
    • Table Global retinoblastoma treatment market: Key drivers
    • Increase in public awareness
    • Increase in incidence of the disease
    • Provision for rare diseases
    • Development of targeted therapies
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Table Global retinoblastoma treatment market: Key challenges
    • Treatment abandonment
    • Limited healthcare access
    • Alternative treatment options
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Localized treatment approach
    • Twinning programs
    • Improving survival rate
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Baxter: Key takeaways
      • Table Bristol Myers-Squibb: Key takeaways
      • Table GlaxoSmithKline: Key takeaways
      • Table Spectrum Pharmaceuticals: Key takeaways
    • Other prominent vendors
  • Key Vendor Analysis
    • Baxter International Inc.
      • Table Baxter International Inc. : Business Segmentation
      • Table Baxter International Inc.: Revenue by Business Segmentation 2013
      • Table Baxter International Inc.: Revenue by Geographical Segmentation 2013
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
      • Table Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Business segmentation 2013
      • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 ($ billion)
      • Table GlaxoSmithKline: Sales by Geography 2013
      • Table GlaxoSmithKline: Pipeline Products 2013
    • Spectrum Pharmaceuticals
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report